Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Want to earn cash today without spending a dime? Discover effective strategies that allow you to generate income quickly.
25,920 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Palantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
When a major hedge fund trims a stake in a diversified telecom, it sends a message to the market. This article breaks...
A sharp global copper crunch boosts Freeport-McMoRan as the leading domestic copper king. Investors eye FCX for cash ...
As rate landscapes shift in 2026, three dividend-focused ETFs provide a disciplined path to durable retirement income...
Spotify unveiled a long-term plan to hit 1 billion active users and sustain 20% operating margins by 2030, highlighti...
This week brought a notable pullback in AI hardware names, including CoreWeave. Read a clear, practical look at what ...
Goldman Sachs flags three natural gas stocks as strong buy candidates as LNG demand tightens and energy markets swing.
As the BNPL market matures, Affirm and Klarna face distinct paths to growth. This guide dives into business models, f...
Apple extends Broadcom’s supply agreement through 2031, anchoring cash flow and accelerating AI chip growth. Here’s w...
When a spouse dies, the survivor may move from joint to single filing, often widening tax brackets and lowering deduc...
As markets warm to AI-driven earnings and liquidity improves, investors are eyeing three likely stock splits in 2026....